Nachrichten zur Johnson & Johnson Aktie

Stocks Mixed, Tesla Muted, Netflix Slumps, Johnson & Johnson On Deck, United Airlines Lift-Off - 5 Things To Know

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Johnson & Johnson, Tesla And 3 Stocks To Watch Heading Into Thursday

With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today…

Johnson & Johnson Prepares for Earnings. Talc Worries Are Top of Mind for Investors.

The company is slated to report its financial results for the second quarter on Thursday....…

Johnson & Johnson Sues HHS Over Medicare Drug Price Negotiation Program

NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (J&J) has filed a lawsuit against the Department of Health and Human Services…

Johnson & Johnson must pay $18.8m to cancer patient in baby powder lawsuit

Jury rules in favor of California man who says he developed a deadly cancer from heavy exposure to talc powder…

Johnson & Johnson Prepares for Earnings. Talc Worrries Are Top of Mind for Investors.

The company is slated to report its financial results for the second quarter on Thursday....…

Babypuder: Johnson & Johnson muss Krebspatient 18,8 Millionen US-Dollar zahlen

Ein 24-Jähriger erkrankt an Krebs und wähnt mutmaßlich belastetes Babypuder als Ursache. Hersteller J&J hält dagegen – nun entschied ein…

J&J ordered to pay $18.8M over baby powder cancer claim, jury rules

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-J&J must pay $18.8 mln to California cancer patient in baby powder suit

...(Adds background on case) By Brendan Pierson July 18 (Reuters.... Reuters watched the trial through Courtroom View Network. J&J has denied......…

J&J must pay $18.8 mln to California cancer patient in baby powder suit

...By Brendan Pierson July 18 (Reuters) - Johnson & Johnsons must pay......…

J&J must pay $18.8 million to California cancer patient in baby powder suit

...By Brendan Pierson (Reuters) - Johnson & Johnsons must pay $18.8......…

Johnson & Johnson joins Merck, others, in fighting Medicare drug-price program

Johnson & Johnson JNJ has joined companies such as Merck & Co. Inc. MRK, Bristol Myers Squibb Co. BMY and…

J&J becomes latest Big Pharma to sue over Medicare drug pricing

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

J&J (JNJ) to Begin Q2 Earnings Season for Drug, Biotech Sector

Growth in J&Js (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex. In the MedTech segment,…

Johnson & Johnson sues Biden administration over Medicare drug price negotiations

Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA filed separate lawsuits against the provision last month....…

J&J sues US govt to halt Medicare drug price negotiation plans

...(Reuters) - Johnson & Johnson sued the U.S. government on Tuesday......…

UPDATE 1-J&J sues US govt to halt Medicare drug price negotiation plans

...(Adds background throughout) July 18 (Reuters) - Johnson & Johnson......…

Earnings week ahead: Tesla, Netflix, Johnson & Johnson, Bank of America and more

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Johnson & Johnson Poised For A Muted Q2?

We expect the companys revenues to come in at $24.6 billion, marginally below the consensus estimate of $24.7 billion....…

Johnson & Johnson Sues Doctors Over Studies Linking Talc-Based Products and Cancer

Company says the studies played a significant role in lawsuits over its Baby Powder and Shower to Shower products....…

Johnson & Johnson Letting Nonprofit Distribute Life-Saving Generic Tuberculosis Drug—Greatly Expanding Access In Poorer Countries

The drug manufacturer faced an online pressure campaign championed by novelist John Green before the announcement Thursday, which lets Stop…

Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth

Johnson & Johnson (JNJ) doesnt possess the right combination of the two key ingredients for a likely earnings beat in…

Is Johnson & Johnson Stock Overvalued?

The stocks premium valuation could be justified....…

FDA classifies J&J electrode recall as most serious type

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Jurors urged to impose heavy punitive damages in J&J talc trial

...By Brendan Pierson July 10 (Reuters) - Lawyers for a California man......…

Johnson & Johnson 2Q financial results could beat even as pharma sales weigh

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Johnson & Johnson 2Q results could beat even as pharma sales weigh

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nanobiotix Shares Soar on Licensing Deal With J&J Unit >NBTX

Nanobiotix Shares Soar on Licensing Deal With J&J Unit >NBTX...…

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…

Is Johnson & Johnson Stock a Buy Now?

Some businesses never go out of style....…

Is Johnson & Johnson Stock a Buy?

Lets take a look at this Dividend King after its spin-off of Kenvue and its proposed $8.7 billion litigation settlement....…

2 Reasons to Buy Johnson & Johnson, and 1 Reason to Sell

This pharma company has reached an important transition point....…

Bausch + Lomb Buys Blink Eye Drop From J&J for $106.5M

Bausch + Lomb Buys Blink Eye Drop From J&J for $106.5M...…

Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R)…

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

Phase 2b FRONTIER 1 data presentation at World Congress of Dermatology highlights that a greater proportion of patients achieved 75,…

dpa-AFX ProFeed